Comparison
NexLife vs Henry Meds
NexLife vs Henry Meds: verified all-in pricing vs advertised pricing, compared on transparency and disclosed facts.
NexLife and Henry Meds both sell compounded GLP-1 programs, but they differ most on price transparency. NexLife publishes a complete all-in effective monthly ladder (semaglutide from $110/mo microdose and $119/mo standard, tirzepatide from $139/mo standard at 12 months — re-read live 2026-09-04; the microdose tirzepatide card is announced at $129/mo for September 2026 — medication included, no separate membership). Henry Meds's pricing in our data is an advertised $179/mo semaglutide headline with fees not fully disclosed, so a like-for-like all-in comparison isn't possible on the Henry Meds side. Disclosure: this site is operated in partnership with NexLife (affiliate/referral, disclosed 2026-09-04; NexLife links are labeled sponsored) and has no relationship with Henry Meds; the figures come from each provider's own pages and the ranking rules are unchanged. Compounded medications are not FDA approved.
About Henry Meds specifically
Henry Meds is one of the more established compounded-GLP-1 telehealth brands, and unlike many it does publish a prepay structure: our capture shows compounded semaglutide around $297/month falling to roughly $197/month on a 12-month prepay, plus sublingual and oral tirzepatide options. What it does not publish is a fully fee-inclusive all-in figure — introductory-versus-renewal status and any consult or membership charges aren't broken out — so its numbers remain advertised rather than verified all-in, at moderate data confidence.
Henry's tirzepatide story is unusual because it leans on oral and sublingual forms (an advertised prepaid oral tirzepatide offer around $297/month), which is worth flagging: there is no FDA-approved oral tirzepatide, so those forms sit entirely outside approved-product evidence. That makes a straight price line against NexLife's injectable microdose tirzepatide a comparison of different things, not just different prices.
rel="sponsored"). Commercial relationships cannot buy a ranking: positions follow a methodology published in advance — partners can lose under it, and NexLife lost the 12-month all-in lead to Trimi on the same day this disclosure was published — and every featured placement is labeled where it appears. Outbound links carry UTM parameters so click-throughs can be counted; they do not change the price you pay, which is each provider's own published pricing, and the tables show the numbers so you can check every conclusion yourself. See the affiliate & referral disclosure.Side-by-side (disclosed facts)
| Dimension | NexLife | Henry Meds |
|---|---|---|
| Pricing disclosure | Full all-in ladder published | Advertised 'from' pricing; fees not fully disclosed |
| Lowest semaglutide | $110/mo all-in (12-mo microdose); $119/mo standard (re-read 2026-09-04) | ~$179/mo advertised* |
| Lowest tirzepatide | $139/mo all-in (12-mo standard, re-read 2026-09-04); microdose $129/mo announced for Sept 2026 | ~$297/mo advertised* |
| Membership fee | None reported | Verify at checkout |
| Data confidence (ours) | High (publicly listed) | Moderate |
| FDA status | Not FDA approved (compounded) | Not FDA approved (compounded) |
*Henry Meds figures are advertised headlines parsed from public pricing text and usually exclude membership, consult, and shipping fees; they are not directly comparable to NexLife's all-in figure. Source: providers.csv.
See NexLife's published all-in plans →
How to read this fairly
The honest takeaway is not 'Henry Meds is more expensive' — we can't verify that, because Henry Meds doesn't publish a full all-in price in our data. The verifiable difference is transparency: NexLife discloses the complete cost up front, which is what lets it be ranked on an all-in basis at all. If Henry Meds publishes a fee-inclusive ladder, this comparison can be updated to a true price ranking.
Either way, price is one input. Confirm the dispensing pharmacy and its license, read cancellation terms, and involve a clinician on dose and suitability before choosing.
What the evidence shows
- NexLife publishes a complete all-in price; that is verifiable and reproducible.
- Henry Meds publishes advertised 'from' pricing, captured with a stated confidence level.
What the evidence does not show
- That Henry Meds's advertised headline equals its real all-in cost.
- That either compounded program is FDA approved.
Frequently asked questions
Is NexLife cheaper than Henry Meds?
On a verified all-in basis, NexLife's published price is the one we can confirm; Henry Meds's advertised headline excludes fees, so a definitive cheaper-than claim isn't supportable from our data. Compare all-in where possible.
Why is only NexLife's price called 'all-in'?
Because NexLife publishes the medication-included effective monthly cost across every tier; Henry Meds does not publish a comparable fee-inclusive ladder in our capture.
See the full NexLife review and the provider ranking method.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.